ClinicalTrials.gg
WithdrawnNCT05614817Updated Mar 21, 2023

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

A Phase 3 interventional study of CBP-201 and Placebo in Atopic Dermatitis, sponsored by Connect Biopharm LLC. Withdrawn. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-03-21.

Sponsored by Connect Biopharm LLC · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12 years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.

Read the detailed description

This study is comprised of a 2- to 6-week (Day-45 to Day 1) Screening Period, a 16-week randomized, double-blind Treatment Period 1, a 36-week Treatment Period 2, and an 8-week follow-up after the last dose of study drug. Therefore, participants will be enrolled in the trial for a maximum of 66 weeks.

02

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
  • allergic dermatitis
  • pruritis
  • type 2 inflammation
  • allergy
03

In context

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Lead sponsor

Connect Biopharm LLC is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

  • Able to provide written or assent (as per local law).
  • Adults and adolescents of any sex or gender (12 years of age or older)
  • Body weight ≥ 40 kg at Screening
  • Diagnosis of chronic Atopic Dermatitis as defined according to American Academy of Dermatology Consensus Criteria (Eichenfield 2014), present ≥ 3 year before Screening.

Atopic Dermatitis history with ALL the following disease activity criteria:

  1. Involvement of ≥ 10% BSA at Screening and Baseline (Day 1).
  2. An EASI score of ≥ 16 at Screening and Baseline (Day 1).
  3. An IGA score of ≥ 3 at Screening and Baseline (Day 1).
  4. Baseline weekly average of daily PP-NRS ≥ 4 at Baseline (Day1).

    • Participant has applied a Sponsor approved emollient twice a day for at least 14 days before the Baseline Visit and agree to continue at least daily use during study participation.
    • Documented recent history (within 180 days before Screening) of inadequate response to treatment with TCS or topical immunomodulator medication or for whom topical treatments are otherwise medically inadvisable (e.g., important side effects or safety risks).
    • Participants must agree to avoid the use of prohibited AD medications throughout the duration of the study.
    • In the opinion of the Investigator, participant is willing and able to comply with all study visits and study-related procedures.
    • Female patients of who are sexually active with a non-sterilized male partner should have a confirmed negative serum beta-human chorionic gonadotropin test at Visit 1 and agrees to use acceptable forms of .

Exclusion criteria

Exclusion Criteria:

-

No current or past history of:

  1. Other active skin diseases (e.g., psoriasis, lupus erythematosus etc.) or skin infections (bacterial, fungal, or viral) that require systemic treatment within 4 weeks of Screening Visit or would interfere with the assessment of AD lesions.
  2. History of recurrent herpes herpeticum in the prior 12 months or more than 2 episodes of herpes herpeticum in past 2 years.
  3. Non-skin related active infection requiring systemic treatment with parenteral anti-infectives within 30 days or oral anti-infectives within 14 days before the Baseline Visit (Visit 2).
  4. Active (HIV) defined as a confirmed positive anti-HIV antibody test.
  5. Tuberculosis requiring treatment within the past 12 months before Screening. Note: Evaluation of tuberculosis will be according to local guidelines as per standard of care.
  6. Active virus (HBV) or virus (HCV).
  7. HCV: HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody (HCV Ab).

    •

Participant may not have any of the following conditions:

  1. Known primary immunodeficiency or
  2. History of within 5 years before the Screening Visit except for completely treated in situ carcinoma of the cervix or completely treated and resolved basal cell carcinoma of the skin.
  3. A helminth parasitic infection diagnosed within 6 months before Visit 1 that has not been treated with or has failed to respond to standard of care therapy.
  4. History of chronic alcohol or drug abuse including chronic use of cannabis (e.g., inhalation and/or consumption of marijuana more than once per week) within 12 months before screening.
  5. History of attempted suicide or is at significant risk of suicide.
  6. History of anaphylaxis after administration of a biologic medication or vaccine.
  7. History of (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study drug [L-histidine, trehalose, or Tween (polysorbate) 80].
  8. Any disorder, including, but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: affect participant safety, alter the findings of the study or the interpretation of study results, impede the participant's ability to complete the entire duration of the study, or would require frequent bursts of systemic .

    • Participant may not have Prior/Concomitant Therapy as follows:

a. Receipt of live (attenuated) vaccines within 30 days of Baseline (Day 1) NOTE: Receipt of inactive/killed vaccines (e.g., influenza) or mRNA vaccines (e.g., COVID) are permitted provided that they are not given within 5 days before/after any of the study visits.

b. Receipt or donation of any blood product in the 28 days before Baseline (Day 1).

NOTE: Patients who are not willing to abstain from donating blood and/or plasma from Screening and for the 112 days after last dose of study drug should not be enrolled.

•

Participant is unable or unwilling to discontinue current prohibited AD treatments within defined washout windows below and in prohibited medications Section 6.11, as applicable, before Baseline (Visit 2):

  1. Systemic JAK inhibitors including but not limited to ruxolitinib, tofacitinib, baricitinib, upadacitinib, abrocitinib and filgotinib within 60 days
  2. Lymphocyte depleting agents such as rituximab within 6 months or when lymphocyte counts return to normal whichever is longer
  3. Systemic therapy for AD including but not limited to corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE-4) inhibitors, or mycophenolate mofetil within 4 weeks
  4. Targeted biologic treatments (as listed in prohibited medication Section 6.11) within 5 half-lives (if known) or 12 weeks, whichever is longer
  5. At any time prior to baseline, patient did not respond favorably to previous dupilumab or other anti-IL4Rα or anti-IL-13 treatment (e.g., therapy failure, patient experienced an adverse reaction to treatment)
  6. Oral or parenteral traditional Chinese medicine within 4 weeks
  7. Topical treatments other than the Sponsor permitted emollient, including but not limited to TCS, TCI, PDE-4, antihistamines, or JAKi within 2 weeks
  8. Phototherapy treatment, laser therapy, tanning booth, or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks
  9. Use of bleach baths in the prior 2 weeks
  10. Topical anti-infectives within 2 weeks
  11. Emollients only available by prescription within 2 weeks including those containing ceramide, hyaluronic acid, urea, filaggrin, Vitamin D or Vitamin E, even if not prescribed Prior/Concurrent Clinical Study Experience

    • Receipt of any experimental systemic medications in the 42 days before Baseline (Day 1), or 5 half-lives (if known), whichever is longer.
    • Previous enrollment in a CBP-201 treatment protocol and having received at least 1 dose of active study drug.
    • Concurrent enrollment in another trial where the patient is receiving an experimental intervention.

Have the following laboratory abnormalities at Screening:

  1. ≤ 10 g/dL
  2. count \< 100,000 cells/µL
  3. Eosinophil count > 1500 cells/ µL
  4. Total creatine phosphokinase (CPK) > 3 times the (ULN)
  5. (ALT) ≥ 2.0xULN
  6. Aspartate aminotransferase (AST) ≥ 2.0x ULN
  7. Total ≥ 1.5x ULN (an isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated, and the direct bilirubin is \< 35% or if the participant has known Gilbert's Syndrome)
  8. Alkaline Phosphatase >2x ULN

    • Abnormal at screening per investigator assessment.
    • Major surgery, requiring anesthesia, within 6 weeks before Baseline (Day 1), or planned in-patient surgery or hospitalization during study participation.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    [Treatment Period 1]Group 1-Dose1

    CBP-201 600 mg (4 mL) SC on Day 1 (Week 0 visit) visit followed by 300 mg (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14.

    Drug: CBP-201

  • Placebo comparator
    [Treatment Period 1]Goup 2-Placebo1

    Placebo (4 mL) SC on Day 0 (Week 0) visit followed by placebo (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14

    Drug: Placebo

  • Experimental
    [Treatment Period 2] Group 1-Dose2

    CBP-201 300 mg SC Q2W starting at Week 16 with the last dose at Week 50 Treatment Period 2 (Group 1 Dose 1 responder pts that rerandomize to Dose 2, Dose 3, or PBO 2)

    Drug: CBP-201

  • Experimental
    [Treatment Period 2] Group 1-Dose3

    CBP-201 300 mg SC Q4W starting at Week 16, alternating with placebo SC Q4W starting at Week 18 with the last dose of CBP-201 at Week 48 and placebo at Week 50

    Drug: CBP-201

  • Placebo comparator
    [Treatment Period 2] Group 1-Placebo2

    Placebo Q2W SC starting at Week 16 with the last dose at Week 50

    Drug: Placebo

  • Placebo comparator
    [Treatment Period 2] Group 2-Placebo

    PBO 1 pts responders that continue PBO 1

    Drug: Placebo

  • Experimental
    [Treatment Period 2] Group 3-Dose

    Dose 1 and PBO 1 Non-responders, and Group 1 and 2 Non-responders that get open-label Dose 4 or 5 (LD 300 mg or 600 mg, biweekly 300 mg thereafter)

    Drug: CBP-201

Interventions

  • CBP-201 subcutaneous(SC) injection

  • DrugPlacebo

    subcutaneous(SC) injection

06

What researchers measure

Primary outcomes

  1. Investigator Global Assessment(IGA)(0-1)

    The proportion of participants whose IGA score is 0-1 and decreased by ≥2 points

    Time frame: Baseline to Week16

  2. EASI-75

    The proportion of participants achieving EASI-75

    Time frame: Baseline at Week 16

Secondary outcomes

  1. Change in Peak Pruritus Numerical Rating Scale(PP-NRS)(in the US)

    The proportion of participants achieving an improvement (reduction) of ≥4 on Peak Pruritis numeric rating scale (PP-NRS)

    Time frame: Baseline at Week16

  2. Investigator Global Assessment(IGA)(0-1) (outside of the US)

    Proportion of participants achieving an IGA score of 0 or 1 and a 2-grade improvement in IGA

    Time frame: Baseline at Week16

  3. Change in Peak Pruritus Numerical Rating Scale(PP-NRS)(outside of the US)

    Proportion of participants achieving an improvement (reduction) of ≥4 on PP-NRS

    Time frame: Baseline at Week16

  4. Scoring Atopic Dermatitis(outside of the US)

    Change in Scoring Atopic Dermatitis (SCORAD)

    Time frame: At Week16

  5. Dermatology Life Quality Index(outside of the US)

    Change in Dermatology Life Quality Index (DLQI) score

    Time frame: Baseline at Week16

  6. EASI-90

    Proportion of participants achieving 90% reduction in EASI score

    Time frame: Baseline at Week16

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2022; primary completion for Aug 2024, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2022
First posted
Nov 14, 2022
StartEst.
Dec 2022
Primary completionEst.
Aug 2024
CompletionEst.
Jul 2025
Last update
Mar 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05614817
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Dec 2022 (estimated)
Primary completion
Aug 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Mar 21, 2023

Study contacts

Suzhou Connect
study director · Connect Biopharm LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion